DOP2013000003A - A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH GLYCOL POLYETHYLENE - Google Patents

A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH GLYCOL POLYETHYLENE

Info

Publication number
DOP2013000003A
DOP2013000003A DO2013000003A DO2013000003A DOP2013000003A DO P2013000003 A DOP2013000003 A DO P2013000003A DO 2013000003 A DO2013000003 A DO 2013000003A DO 2013000003 A DO2013000003 A DO 2013000003A DO P2013000003 A DOP2013000003 A DO P2013000003A
Authority
DO
Dominican Republic
Prior art keywords
conjugate
csf
stimulating factor
new
granulocit
Prior art date
Application number
DO2013000003A
Other languages
Spanish (es)
Inventor
Lev Alexandrovich Denisov
Dmitriy Valentinovich Morozov
Elena Georgievna Rudenko
Tatyana Veniaminovna Chernovskaya
Elena Leonidovna Morozova
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000003(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of DOP2013000003A publication Critical patent/DOP2013000003A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a farmacéuticos y medicina, específicamente, a un nuevo conjugado fisiológicamente de granulocita colonia estimulante factor (G-CSF) con la fórmula general: Donde: n — intergers de 681 a 1 000; m — interger ? 4; NaHGCSF — Natural o recombinante polipéptido, teniendo actividad de G-CSF La invención también está relacionada a medicinas conteniendo el conjugado reclamado de fórmula (1), composiciones farmacéuticas, el uso de conjugado de fórmula (1) para drogas y medicinas con granulocita colonia estimulante factor como un ingrediente activo, se aproxima a prevenir yio tratar la neutropenia, el contenedor que contiene la composición farmacéutica.The present invention relates to pharmacists and medicine, specifically, to a new physiologically conjugated granulocyte colony stimulating factor (G-CSF) with the general formula: Where: n - intergers from 681 to 1 000; m - interger? 4; NaHGCSF - Natural or recombinant polypeptide, having G-CSF activity The invention also relates to medicines containing the claimed conjugate of formula (1), pharmaceutical compositions, the use of conjugate of formula (1) for drugs and medicines with granulocyte stimulating colony As an active ingredient, it is close to preventing and treating neutropenia, the container that contains the pharmaceutical composition.

DO2013000003A 2010-08-13 2013-01-04 A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH GLYCOL POLYETHYLENE DOP2013000003A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent

Publications (1)

Publication Number Publication Date
DOP2013000003A true DOP2013000003A (en) 2013-07-31

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000003A DOP2013000003A (en) 2010-08-13 2013-01-04 A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH GLYCOL POLYETHYLENE

Country Status (17)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
ES2691493T3 (en) 2012-06-07 2018-11-27 Childrens Hospital Los Angeles Methods to treat neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
JP6742300B2 (en) * 2014-07-14 2020-08-19 ジェンノヴァ バイオファーマシューティカルズ リミテッド Novel process for purification of rHu-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
BR112022018501A2 (en) * 2020-03-17 2022-10-25 Drugrecure Aps LIQUID FORMULATION OF GM-CSF FOR INHALATION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135370T1 (en) * 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease

Also Published As

Publication number Publication date
CU24139B1 (en) 2015-12-23
EA201101035A1 (en) 2012-02-28
RU2446173C1 (en) 2012-03-27
CO6670557A2 (en) 2013-05-15
PE20131085A1 (en) 2013-10-10
CN103140499A (en) 2013-06-05
MA34525B1 (en) 2013-09-02
KR101549457B1 (en) 2015-09-02
SG187572A1 (en) 2013-03-28
MY160732A (en) 2017-03-15
WO2012021088A1 (en) 2012-02-16
ECSP13012399A (en) 2013-05-31
NI201300007A (en) 2014-05-26
KR20130043167A (en) 2013-04-29
EA019043B1 (en) 2013-12-30
CN103140499B (en) 2014-12-17
CL2013000400A1 (en) 2013-07-26
RS20130094A1 (en) 2013-08-30
CR20130020A (en) 2013-02-20
CU20130012A7 (en) 2013-04-19

Similar Documents

Publication Publication Date Title
DOP2013000003A (en) A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH GLYCOL POLYETHYLENE
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
NZ704011A (en) Abuse deterrent pharmaceutical compositions for controlled release
BR112013003045A2 (en) compound and pharmaceutical composition and uses thereof, sterile container and method for preparing pharmaceutical composition for administration
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
EA201390409A1 (en) COMPOSITIONS WITH LOW DOSE OF PANCRELIPASE AND INTESTINAL-SOLUBLE COATING
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
EA201590805A1 (en) COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY
EA201291089A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS
MX2011011829A (en) Composition for sustained drug delivery comprising geopolymeric binder.
MY168784A (en) The new stable polyethylene glycol conjugate of interferon alpha,represented by one positional isomer
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EA201401309A1 (en) PHARMACEUTICAL COMPOSITION FOR INHALATION, CONTAINING ACHYDINE, AND ITS APPLICATION
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
EP2682100A3 (en) Inhalation Compositions Comprising Muscarinic Receptor Antagonist
MX2015015150A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
BR112013006651A2 (en) composition and cocrystal of l-proline aprepitant
CY1115600T1 (en) Piperazines as Anthelmintic Agents
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
MX2015010594A (en) Lipobalanced long chain testosterone esters for oral delivery.
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
AR074470A1 (en) AMIDA COMPOUND OF THE CYCLOPROPANOCARBOXYL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES
MX2017013634A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a powder.
EA200801854A1 (en) NEW COMPOSITIONS